Journals / Viral Hepatitis Journal / 2012 / Cilt: 18 - Sayı: 3

Karaciğer Biyopsisi Deneyimi

Liver Biopsy Experience

Pages
115–119
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This negativity can be reduced by increased experience.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the frequency of complications and insufficient material rates of liver biopsies and association with experience in liver biopsies that made for diagnosis of chronic viral hepatitis.
📊
Key Findings & Data:Materials and Methods: We retrospectively reviewed our four years liver biopsy experience between 2008-2011.
💡
Conclusion & Impact:This negativity can be reduced by increased experience.
🔬Design:Review & Systematic Survey
📍Scope:2008-2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To investigate the frequency of complications and insufficient material rates of liver biopsies and association with experience in liver biopsies that made for diagnosis of chronic viral hepatitis. Materials and Methods: We retrospectively reviewed our four years liver biopsy experience between 2008-2011. The records of patients were investigated retrospectively. In our clinic, the number of doctors perform a liver biopsy and doctors with experience were recorded. Tabulation was performed and student’s t-test and X2 test was used for statistical method. P<0.05 was considered statistically significant. Results: Data of 305 liver biopsy has been reached in the study period. Biopsy-related complication rate was found 3.1% (serious complication 0.3%, non-serious complication 2.8%). Receiving rate of insufficient material was decreased with experience and was found to be 25%, 17 %, 8%, 5.4% in 2008-2011, respectively (p<0.05). The rate of insufficient material by increased experience, in 2011 dropped to 5.4%. Of all the cases called for biopsy, it was detected that 33 cases (9.7%) refused liver biopsy. Conclusion: Cory liver biopsy complication rate is low and can be safely applied to patients for the diagnosis of chronic hepatitis. Receiving rate insufficient material and development of complications related to experience of who perform the biopsy. This negativity can be reduced by increased experience.

Özet

Amaç: Kronik viral hepatit tanısı amacıyla yapılan karaciğer biyopsilerinde, komplikasyon ve yetersiz materyal alma nedenleri ve sıklığını ve deneyimle ilişkisini araştırmak amaçlanmıştır. Gereç ve Yöntemler: 2008-2011 yılları arasındaki dört yıllık dönemde karaciğer biyopsi deneyimlerimizi retrospektif olarak değerlendirdik. Hastalarımıza ait kayıtlar retrospektif olarak araştırıldı.Kliniğimizde yıllara göre karaciğer biyopsisi yapan hekim ile hekimlerin yıllara göre tecrübe oranları kaydedildi. Veriler tabule edilerek student’s t-test ve χ2 testi iledeğerlendirildi. P<0,05 anlamlı kabul edildi. Bulgular: Çalışma döneminde 305 karaciğer biyopsi verisine ulaşıldı. Biyopsiye bağlı komplikasyon oranı %3,1 idi (ciddi komplikasyon %0,3, ciddi olmayan komplikasyon %2,8). Yetersiz materyal alma oranı deneyimle azaldı. Yetersiz materyal alma oranı 2008 ile 2011 arasında sırasıyla %25, %17, %8, %5,4 idi (p<0,05). Artan tecrübe ile yetersiz materyal alma oranımız 2011 yılında %5,4’a düştü. Çalışmada biyopsi randevusu verilenlerin 33 (%9,7)’ünün biyopsiyi reddettiği saptandı. Sonuç: Kör yapılan karaciğer biyopsisinin komplikasyon oranı düşüktür ve kronik hepatit tanısı için hastalara güvenle uygulanabilir. Biyopside materyal yetersizliği ve komplikasyon riski, işlemi uygulayan personelin tecrübesiyle ilişkilidir. Artan tecrübeyle bu olumsuzluk azaltılabilir.

🔖

Cite This Article

TUNA, N., YAHYAOĞLU, M., ÖZTÜRK, G., ÖĞÜTLÜ, A., ÇALICA, A. U., DURMAZ, Y., GÖZDAŞ, H. T., GÜÇLÜ, E., KARABAY, O. (2012). Karaciğer Biyopsisi Deneyimi. Viral Hepatitis Journal, Cilt: 18 - Sayı: 3, 115–119. https://ajindex.com/articles/332763

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Thampanitchawong P, Piratvisuth T. Liver biopsy: complications and risk factors. World J Gastroenterol. 1999; 5: 301-4
  2. Czaja AJ, Carpenter HA. Optimizing diagnosis from the medical liver biopsy. Clin Gastroenterol Hepatol. 2007; 5: 898-907
  3. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol. 2006; 12: 3682-94
  4. Bravo AA, Sheth SG, Chopra S. Liver Biopsy. N Engl J Med. 2001; 344: 495-500
  5. Vargas-Tank L, Martinez V, Jiron MI, Soto JR, Armas-Merino R. Tru- Cut and Menghini needles: different yield in the histological diagnosis of liver disease. Liver 1985; 5: 178-81
  6. Hopper KD, Baird DE, Reddy VV, Landis JR, Parker SH, Tyler HN Jr, et al. Efficacy of automated biopsy guns versus conventional biopsy needles in the pygmy pig. Radiology. 1990; 176: 671-6. 7. de Man RA, van Buuren HR, Hop WC. A randomised study on the efficacy and safety of an automated Tru-Cut needle for percutaneous liver biopsy. Neth J Med. 2004; 62: 441-5
  7. Cevik FC, Aykin N, Naz H. Complications and efficiency of liver biopsies using the Tru-Cut biopsy Gun. J Infect Dev Ctries. 2010; 4: 91-5
  8. Van Leeuwen DJ, Wilson L, Crowe DR. Liver Biopsy in the mid- 1990s: Questions and answers. Semin Liver Dis. 1995; 15: 340-59
  9. Bonny C, Rayssiguier R, Ughetto S, Aublet-Cuvelier B, Baranger J, Blanchet G, et al. Medical practices and expectations of general practitioners in relation to hepatitis C virus infection in the Auvergne region. Gastroenterol Clin Biol. 2003; 27: 1021-5
  10. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology. 2002; 36: (Suppl 1): 152-60
  11. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales:an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut. 1995; 36: 437-41. 13. http://www.uptodate.com/ contents/percutaneous-liver-biopsy 14. Myers RP, Fong A, Shaheen AA.Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int. 2008; 28: 705-12
  12. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986;2(2):165-73
  13. Turhan V, Acar A, Küçükodacı Z et al. Kronik viral hepatiti bulunan 1380 hastada uygulanan perkütan kör